Humacyte (HUMA) Stock Forecast, Price Target & Predictions
HUMA Stock Forecast
Humacyte stock forecast is as follows: an average price target of $7.00 (represents a 38.07% upside from HUMA’s last price of $5.07) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
HUMA Price Target
The average price target for Humacyte (HUMA) is $7.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $5.00. This represents a potential 38.07% upside from HUMA's last price of $5.07.
HUMA Analyst Ratings
According to 5 Wall Street analysts, Humacyte's rating consensus is 'Buy'. The analyst rating breakdown for HUMA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Humacyte Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 18, 2024 | Matt O'Brien | Piper Sandler | $6.00 | $4.86 | 23.46% | 18.34% |
| Oct 18, 2024 | Ryan Zimmerman | BTIG | $10.00 | $4.86 | 105.76% | 97.24% |
| Dec 20, 2022 | Cowen Cowen | Cowen & Co. | $5.00 | $2.21 | 126.50% | -1.38% |
| May 15, 2022 | Matt O'Brien | Piper Sandler | $4.00 | $5.37 | -25.51% | -21.10% |
The latest Humacyte stock forecast, released on Oct 18, 2024 by Matt O'Brien from Piper Sandler, set a price target of $6.00, which represents a 23.46% increase from the stock price at the time of the forecast ($4.86), and a 18.34% increase from HUMA last price ($5.07).
Humacyte Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 2 |
| Avg Price Target | $8.00 | $8.00 | $8.00 |
| Last Closing Price | $5.07 | $5.07 | $5.07 |
| Upside/Downside | 57.79% | 57.79% | 57.79% |
In the current month, the average price target of Humacyte stock is $8.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 57.79% increase as opposed to Humacyte's last price of $5.07. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 18, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 18, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Oct 18, 2024 | BTIG | Buy | Buy | Hold |
| Sep 09, 2024 | EF Hutton | - | Buy | Initialise |
| Sep 05, 2024 | Benchmark | Buy | Buy | Hold |
| Aug 27, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jun 17, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 14, 2023 | Piper Sandler | - | Neutral | Upgrade |
Humacyte's last stock rating was published by Cowen & Co. on Oct 18, 2024. The company gave HUMA a "Buy" rating, the same as its previous rate.
Humacyte Financial Forecast
Humacyte Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $362.59M | $348.64M | $348.64M | $334.70M | $167.81M | $161.36M | $161.36M | $154.90M | $76.25M | $73.32M | $73.32M | $70.39M | $7.05M | $3.93M | $3.31M | $2.50M | $350.00K | $300.00K | $20.00K | $20.00K | $50.00K | $66.67K | $66.67K | $155.60K | $235.40K | $203.50K | $235.40K | $235.40K | $245.67K | $371.67K |
| High Forecast | $362.59M | $348.64M | $348.64M | $334.70M | $167.81M | $161.36M | $161.36M | $154.90M | $76.25M | $73.32M | $73.32M | $70.39M | $7.05M | $3.93M | $3.31M | $2.50M | $350.00K | $300.00K | $20.00K | $20.00K | $50.00K | $66.83K | $66.67K | $155.60K | $235.40K | $203.50K | $235.40K | $235.40K | $245.67K | $371.67K |
| Low Forecast | $362.59M | $348.64M | $348.64M | $334.70M | $167.81M | $161.36M | $161.36M | $154.90M | $76.25M | $73.32M | $73.32M | $70.39M | $7.05M | $3.93M | $3.31M | $2.50M | $350.00K | $300.00K | $20.00K | $20.00K | $50.00K | $66.50K | $66.67K | $155.60K | $235.40K | $203.50K | $235.40K | $235.40K | $245.67K | $371.67K |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Humacyte's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. HUMA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Humacyte EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-26.18M | $-24.62M | $-20.16M | $-8.32M | $-37.91M | $-20.58M | $-16.21M | $-19.69M | $-21.63M | $-30.35M |
| Avg Forecast | $-217.55M | $-209.18M | $-209.18M | $-200.82M | $-100.69M | $-96.81M | $-96.81M | $-92.94M | $-45.75M | $-43.99M | $-43.99M | $-42.23M | $-4.23M | $-2.36M | $-1.99M | $-1.50M | $-210.00K | $-180.00K | $-12.00K | $-12.00K | $-30.00K | $-40.00K | $-40.00K | $-93.36K | $-141.24K | $-122.10K | $-141.24K | $-22.17M | $-147.40K | $-16.67M |
| High Forecast | $-217.55M | $-209.18M | $-209.18M | $-200.82M | $-100.69M | $-96.81M | $-96.81M | $-92.94M | $-45.75M | $-43.99M | $-43.99M | $-42.23M | $-4.23M | $-2.36M | $-1.99M | $-1.50M | $-210.00K | $-180.00K | $-12.00K | $-12.00K | $-30.00K | $-39.90K | $-40.00K | $-93.36K | $-141.24K | $-122.10K | $-141.24K | $-17.73M | $-147.40K | $-13.34M |
| Low Forecast | $-217.55M | $-209.18M | $-209.18M | $-200.82M | $-100.69M | $-96.81M | $-96.81M | $-92.94M | $-45.75M | $-43.99M | $-43.99M | $-42.23M | $-4.23M | $-2.36M | $-1.99M | $-1.50M | $-210.00K | $-180.00K | $-12.00K | $-12.00K | $-30.00K | $-40.10K | $-40.00K | $-93.36K | $-141.24K | $-122.10K | $-141.24K | $-26.60M | $-147.40K | $-20.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 872.73% | 615.55% | 504.05% | 89.13% | 268.39% | 168.52% | 114.76% | 0.89% | 146.71% | 1.82% |
undefined analysts predict HUMA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Humacyte's previous annual EBITDA (undefined) of $NaN.
Humacyte Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-25.11M | - | $-22.71M | $-61.84M | $13.57M | $-25.43M | $92.27M | $-16.47M | - | $-31.56M |
| Avg Forecast | $202.42M | $197.63M | $200.71M | $193.54M | $89.23M | $87.74M | $89.75M | $85.91M | $34.32M | $34.69M | $37.59M | $35.01M | $-26.30M | $-26.94M | $-26.10M | $-26.50M | $-28.25M | $-29.48M | $-28.41M | $-26.92M | $-28.61M | $-30.29M | $-26.21M | $-25.04M | $-27.98M | $-25.54M | $-25.96M | $-24.72M | $-24.37M | $-17.36M |
| High Forecast | $202.42M | $197.63M | $200.71M | $193.54M | $89.23M | $87.74M | $89.75M | $85.91M | $34.32M | $34.69M | $37.59M | $35.01M | $-26.30M | $-26.94M | $-26.10M | $-26.50M | $-28.25M | $-29.48M | $-28.41M | $-26.92M | $-27.47M | $-30.29M | $-26.21M | $-25.04M | $-27.98M | $-25.54M | $-25.96M | $-24.72M | $-24.37M | $-13.89M |
| Low Forecast | $202.42M | $197.63M | $200.71M | $193.54M | $89.23M | $87.74M | $89.75M | $85.91M | $34.32M | $34.69M | $37.59M | $35.01M | $-26.30M | $-26.94M | $-26.10M | $-26.50M | $-28.25M | $-29.48M | $-28.41M | $-26.92M | $-28.61M | $-30.29M | $-26.21M | $-25.04M | $-27.98M | $-25.54M | $-25.96M | $-24.72M | $-24.37M | $-20.83M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.88% | - | 0.87% | 2.47% | -0.49% | 1.00% | -3.55% | 0.67% | - | 1.82% |
Humacyte's average Quarter net income forecast for Mar 23 is $-25.04M, with a range of $-25.04M to $-25.04M. HUMA's average Quarter net income forecast represents a -284.46% decrease compared to the company's last Quarter net income of $13.57M (Dec 22).
Humacyte SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.00M | $6.07M | $3.08M | $5.23M | $5.83M | $6.19M | $5.18M | $5.68M | $15.73M | $5.40M |
| Avg Forecast | $3.12B | $3.00B | $3.00B | $2.88B | $1.44B | $1.39B | $1.39B | $1.33B | $656.38M | $631.14M | $631.14M | $605.89M | $60.70M | $33.86M | $28.48M | $21.56M | $3.01M | $2.58M | $172.16K | $172.16K | $430.39K | $573.86K | $573.86K | $1.34M | $2.03M | $1.75M | $2.03M | $2.03M | $2.11M | $3.20M |
| High Forecast | $3.12B | $3.00B | $3.00B | $2.88B | $1.44B | $1.39B | $1.39B | $1.33B | $656.38M | $631.14M | $631.14M | $605.89M | $60.70M | $33.86M | $28.48M | $21.56M | $3.01M | $2.58M | $172.16K | $172.16K | $430.39K | $575.29K | $573.86K | $1.34M | $2.03M | $1.75M | $2.03M | $2.03M | $2.11M | $3.20M |
| Low Forecast | $3.12B | $3.00B | $3.00B | $2.88B | $1.44B | $1.39B | $1.39B | $1.33B | $656.38M | $631.14M | $631.14M | $605.89M | $60.70M | $33.86M | $28.48M | $21.56M | $3.01M | $2.58M | $172.16K | $172.16K | $430.39K | $572.42K | $573.86K | $1.34M | $2.03M | $1.75M | $2.03M | $2.03M | $2.11M | $3.20M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.95% | 10.58% | 5.37% | 3.91% | 2.88% | 3.53% | 2.56% | 2.80% | 7.44% | 1.69% |
Humacyte's average Quarter SG&A projection for Mar 24 is $172.16K, based on 2 Wall Street analysts, with a range of $172.16K to $172.16K. The forecast indicates a -97.13% fall compared to HUMA last annual SG&A of $6.00M (Dec 23).
Humacyte EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 5 | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.24 | - | $-0.22 | $-0.60 | $0.13 | $-0.25 | $0.90 | $-0.16 | - | $-0.72 |
| Avg Forecast | $1.70 | $1.66 | $1.68 | $1.62 | $0.75 | $0.74 | $0.75 | $0.72 | $0.29 | $0.29 | $0.32 | $0.29 | $-0.22 | $-0.23 | $-0.22 | $-0.22 | $-0.24 | $-0.25 | $-0.24 | $-0.23 | $-0.24 | $-0.25 | $-0.22 | $-0.21 | $-0.23 | $-0.21 | $-0.22 | $-0.21 | $-0.20 | $-0.20 |
| High Forecast | $1.70 | $1.66 | $1.68 | $1.62 | $0.75 | $0.74 | $0.75 | $0.72 | $0.29 | $0.29 | $0.32 | $0.29 | $-0.22 | $-0.23 | $-0.22 | $-0.22 | $-0.24 | $-0.25 | $-0.24 | $-0.23 | $-0.23 | $-0.25 | $-0.22 | $-0.21 | $-0.23 | $-0.21 | $-0.22 | $-0.21 | $-0.20 | $-0.20 |
| Low Forecast | $1.70 | $1.66 | $1.68 | $1.62 | $0.75 | $0.74 | $0.75 | $0.72 | $0.29 | $0.29 | $0.32 | $0.29 | $-0.22 | $-0.23 | $-0.22 | $-0.22 | $-0.24 | $-0.25 | $-0.24 | $-0.23 | $-0.24 | $-0.25 | $-0.22 | $-0.21 | $-0.23 | $-0.21 | $-0.22 | $-0.21 | $-0.20 | $-0.20 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | - | 1.00% | 2.86% | -0.55% | 1.17% | -4.13% | 0.77% | - | 3.51% |
According to 2 Wall Street analysts, Humacyte's projected average Quarter EPS for Mar 23 is $-0.21, with a low estimate of $-0.21 and a high estimate of $-0.21. This represents a -261.63% decrease compared to HUMA previous annual EPS of $0.13 (Dec 22).
Humacyte Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
| GPCR | Structure Therapeutics | $39.74 | $92.40 | 132.51% | Buy |
| IMCR | Immunocore | $31.17 | $70.75 | 126.98% | Buy |
| KALV | KalVista Pharmaceuticals | $11.63 | $26.00 | 123.56% | Buy |
| LYRA | Lyra Therapeutics | $0.26 | $0.50 | 92.31% | Hold |
| VRDN | Viridian Therapeutics | $22.84 | $37.83 | 65.63% | Buy |
| CYTK | Cytokinetics | $51.48 | $83.23 | 61.67% | Buy |
| KURA | Kura Oncology | $17.81 | $26.00 | 45.99% | Buy |
| HUMA | Humacyte | $5.07 | $7.00 | 38.07% | Buy |
| MIRM | Mirum Pharmaceuticals | $40.45 | $54.50 | 34.73% | Buy |
| NRIX | Nurix Therapeutics | $25.04 | $32.20 | 28.59% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
HUMA Forecast FAQ
Is Humacyte a good buy?
Yes, according to 5 Wall Street analysts, Humacyte (HUMA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of HUMA's total ratings.
What is HUMA's price target?
Humacyte (HUMA) average price target is $7 with a range of $5 to $10, implying a 38.07% from its last price of $5.07. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Humacyte stock go up soon?
According to Wall Street analysts' prediction for HUMA stock, the company can go up by 38.07% (from the last price of $5.07 to the average price target of $7), up by 97.24% based on the highest stock price target, and down by -1.38% based on the lowest stock price target.
Can Humacyte stock reach $8?
HUMA's highest twelve months analyst stock price target of $10 supports the claim that Humacyte can reach $8 in the near future.
What is Humacyte's current price target trend?
2 Wall Street analysts forecast a $8 price target for Humacyte (HUMA) this month, up 57.79% from its last price of $5.07. Compared to the last 3 and 12 months, the average price target increased by 57.79% and increased by 57.79%, respectively.
What are Humacyte's analysts' financial forecasts?
Humacyte's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $645.42M (high $645.42M, low $645.42M), average EBITDA is $-387M (high $-387M, low $-387M), average net income is $352.63M (high $352.63M, low $352.63M), average SG&A $5.56B (high $5.56B, low $5.56B), and average EPS is $2.96 (high $2.96, low $2.96). HUMA's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $1.39B (high $1.39B, low $1.39B), average EBITDA is $-837M (high $-837M, low $-837M), average net income is $794.3M (high $794.3M, low $794.3M), average SG&A $12B (high $12B, low $12B), and average EPS is $6.66 (high $6.66, low $6.66).